Results 101 to 110 of about 4,708 (131)

Extended Postexposure Protection Against Vaginal Simian/Human Immunodeficiency Virus Infection With Tenofovir Alafenamide Fumarate/Elvitegravir Inserts in Macaques. [PDF]

J Infect Dis
Makarova N, Singletary T, Peet MM, Mitchell J, Bachman S, Holder A, Dinh C, Lipscomb J, Agrahari V, Mendoza M, Pan Y, Heneine W, Clark MR, García-Lerma JG, Doncel GF, Smith JM.   +15 more
europepmc   +1 more source

Prospective Analysis of Safety and Efficacy of Tenofovir Alafenamide Fumarate (TAF) in European Real-World Patients with Chronic Hepatitis B: A Single-Centre Real-Word Cohort Study. [PDF]

Pathogens
Fülöp B, Fischer J, Hahn M, Böhlig A, Matz-Soja M, Berg T, van Bömmel F.   +6 more
europepmc   +1 more source

Design of a Drug-Eluting Subcutaneous Implant of the Antiretroviral Tenofovir Alafenamide Fumarate. [PDF]

Pharm Res, 2020
Simpson SM, Widanapathirana L, Su JT, Sung S, Watrous D, Qiu J, Pearson E, Evanoff A, Karunakaran D, Chacon JE, Kiser PF.   +10 more
europepmc   +1 more source

Correction: Relative Bioavailability of Dolutegravir (DTG) and Emtricitabine/Tenofovir Alafenamide Fumarate (F/TAF) Administered as Paediatric Tablet Formulations in Healthy Volunteers. [PDF]

Clin Pharmacokinet
Bevers LAH, Kamphuis AEM, van der Wekken-Pas LCW, Leisegang R, Burger DM, Colbers A.   +5 more
europepmc   +1 more source

Relative Bioavailability of Dolutegravir (DTG) and Emtricitabine/Tenofovir Alafenamide Fumarate (F/TAF) Administered as Paediatric Tablet Formulations in Healthy Volunteers. [PDF]

Clin Pharmacokinet
Bevers LAH, Kamphuis AEM, van der Wekken-Pas LCW, Leisegang R, Burger DM, Colbers A.   +5 more
europepmc   +1 more source

Bone turnover change after randomized switch from tenofovir disoproxil to tenofovir alafenamide fumarate in men with HIV. [PDF]

AIDS
Moore AEB, Burns JE, Sally D, Milinkovic A, Krokos G, John J, Rookyard C, Borca A, Pool ERM, Tostevin A, Harman A, Dulnoan DS, Gilson R, Arenas-Pinto A, Cook GJR, Saunders J, Saunders J, Dunn D, Blake GM, Pett SL.   +19 more
europepmc   +1 more source

Assessment of risk factors for virological nonsuppression following switch to dolutegravir and lamivudine, or bictegravir, emtricitabine, and tenofovir alafenamide fumarate in a real-world cohort of treatment-experienced adults living with HIV. [PDF]

PLoS One
Lee SY, Lin YC, Chen CP, Cheng SH, Chang SY, Ku SY, Cheng CY.   +6 more
europepmc   +1 more source

Letter: Cardiovascular risk of tenofovir disoproxil fumarate or tenofovir alafenamide fumarate in patients with chronic hepatitis B: More questions than an answer - author's reply. [PDF]

Clin Mol Hepatol
Hong H, Choi J.
europepmc   +1 more source

Changes in Glomerular Filtration Rate After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide Fumarate for Human Immunodeficiency Virus Preexposure Prophylaxis. [PDF]

Open Forum Infect Dis
Rivera AS, Pak K, Mefford MT, Hechter RC.   +3 more
europepmc   +1 more source

[Study on the efficacy and safety profile of tenofovir alafenamide fumarate in the treatment of patients with decompensated hepatitis B cirrhosis]. [PDF]

Zhonghua Gan Zang Bing Za Zhi
Guo F, Wu X, Dou J, Ning ZH, Wang XB, Xu Q, Ji FP, Yue YH, Wang ZG, Dang SS, Wang HF, Fu Q, Zeng ST, Zuo WZ, Wang XZ.   +14 more
europepmc   +1 more source